FiscalNote Holdings Valuation
Is A2O undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A2O when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate A2O's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate A2O's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A2O?
Other financial metrics that can be useful for relative valuation.
| What is A2O's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$200.36m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.5x |
| Enterprise Value/EBITDA | -7.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does A2O's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.7x | ||
BDT Bertrandt | 0.3x | 6.5% | €318.3m |
3D6 Avemio | 0.4x | 10.7% | €17.7m |
OJ2 Calvert International | 0.7x | n/a | €2.5m |
AAD Amadeus FiRe | 1.3x | 5.6% | €591.0m |
A2O FiscalNote Holdings | 1.5x | 2.4% | €200.4m |
Price-To-Sales vs Peers: A2O is expensive based on its Price-To-Sales Ratio (1.5x) compared to the peer average (0.6x).
Price to Earnings Ratio vs Industry
How does A2O's PE Ratio compare vs other companies in the European Professional Services Industry?
Price-To-Sales vs Industry: A2O is expensive based on its Price-To-Sales Ratio (1.5x) compared to the European Professional Services industry average (0.9x).
Price to Sales Ratio vs Fair Ratio
What is A2O's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.5x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate A2O's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €1.25 | €2.97 +137.9% | 48.7% | €5.53 | €1.24 | n/a | 5 |
| Jun ’25 | €1.08 | €2.97 +175.0% | 48.7% | €5.53 | €1.24 | n/a | 5 |
| May ’25 | €1.17 | €3.29 +180.7% | 45.3% | €5.48 | €1.60 | n/a | 5 |
| Apr ’25 | €1.17 | €3.29 +181.3% | 45.3% | €5.48 | €1.60 | n/a | 5 |
| Mar ’25 | n/a | €3.49 0% | 71.3% | €6.46 | €0.60 | n/a | 5 |
| Feb ’25 | n/a | €3.49 0% | 71.3% | €6.46 | €0.60 | n/a | 5 |
| Jan ’25 | n/a | €3.49 0% | 71.3% | €6.46 | €0.60 | n/a | 5 |
| Dec ’24 | n/a | €3.49 0% | 71.3% | €6.46 | €0.60 | n/a | 5 |
| Nov ’24 | n/a | €5.53 0% | 40.3% | €8.52 | €2.60 | n/a | 6 |
| Oct ’24 | n/a | €5.31 0% | 40.3% | €8.20 | €2.50 | n/a | 6 |
| Sep ’24 | n/a | €5.31 0% | 40.3% | €8.20 | €2.50 | n/a | 6 |
| Aug ’24 | n/a | €5.37 0% | 41.4% | €8.11 | €1.80 | n/a | 6 |
| Jul ’24 | n/a | €5.60 0% | 43.3% | €8.19 | €1.82 | n/a | 5 |
| Jun ’24 | n/a | €5.95 0% | 44.2% | €8.24 | €1.83 | €1.08 | 4 |
| May ’24 | n/a | €6.17 0% | 44.3% | €8.30 | €1.61 | €1.17 | 4 |
| Apr ’24 | n/a | €6.17 0% | 44.3% | €8.30 | €1.61 | €1.17 | 4 |
| Mar ’24 | n/a | €7.39 0% | 40.7% | €10.32 | €2.34 | n/a | 4 |
| Feb ’24 | n/a | €7.85 0% | 23.0% | €10.01 | €5.01 | n/a | 4 |
| Jan ’24 | n/a | €8.07 0% | 23.0% | €10.30 | €5.15 | n/a | 4 |
| Dec ’23 | n/a | €8.69 0% | 23.9% | €10.62 | €5.31 | n/a | 4 |
| Nov ’23 | n/a | €12.38 0% | 10.4% | €14.01 | €10.51 | n/a | 4 |
| Oct ’23 | n/a | €12.38 0% | 10.4% | €14.01 | €10.50 | n/a | 4 |
| Sep ’23 | n/a | €12.38 0% | 10.4% | €14.01 | €10.50 | n/a | 4 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.